<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00516542</url>
  </required_header>
  <id_info>
    <org_study_id>SOL-06019-L</org_study_id>
    <secondary_id>R21CA119598</secondary_id>
    <secondary_id>P30CA069533</secondary_id>
    <secondary_id>OHSU-e2109</secondary_id>
    <secondary_id>OHSU-IRB00002109</secondary_id>
    <nct_id>NCT00516542</nct_id>
  </id_info>
  <brief_title>Dehydroepiandrosterone (DHEA) and Letrozole in Treating Patients With Metastatic Breast Cancer</brief_title>
  <official_title>A Phase I Study of DHEA in Combination With Letrozole in ER- Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OHSU Knight Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>OHSU Knight Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Androgens can cause the growth of breast cancer cells. Hormone therapy using&#xD;
      dehydroepiandrosterone (DHEA) may fight breast cancer by blocking the use of androgen by the&#xD;
      tumor cells. Letrozole may stop the adrenal glands from making androgens. Giving DHEA&#xD;
      together with letrozole may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of DHEA when given&#xD;
      together with letrozole in treating patients with metastatic breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  To determine the maximum tolerable dose, dose-limiting toxicity, and pharmacokinetics of&#xD;
           dehydroepiandrosterone (DHEA) when given together with letrozole in patients with&#xD;
           androgen receptor-positive and estrogen receptor- and progesterone receptor-negative&#xD;
           metastatic breast cancer.&#xD;
&#xD;
      OUTLINE: Patients receive oral dehydroepiandrosterone and oral letrozole once daily. Physical&#xD;
      exams and blood collections are performed every two weeks. Tumor assessments are performed&#xD;
      once every three months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study was terminated due to lack of accrual&#xD;
  </why_stopped>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting toxicity</measure>
    <time_frame>One year from drug start</time_frame>
    <description>Subjects will be monitored at day 14 and then every 2 weeks for up to one year.</description>
  </primary_outcome>
  <enrollment type="Actual">6</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>letrozole</intervention_name>
    <description>A daily dose of 2.5 mg will be used throughout the study.</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DHEA</intervention_name>
    <description>Will be dispensed in either 500mg or 1000mg tablets. Subjects will start at a dose of 500 mg and may increase up to 5000mg depending on the cohort.</description>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>PK draws will happen on day 1 and day 14, then every 2 weeks.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of breast cancer&#xD;
&#xD;
               -  Metastatic disease&#xD;
&#xD;
          -  Hormone receptor status&#xD;
&#xD;
               -  Estrogen receptor- and progesterone receptor-negative&#xD;
&#xD;
               -  Androgen receptor-positive&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-3&#xD;
&#xD;
          -  Postmenopausal (&gt; 60 years of age)&#xD;
&#xD;
          -  Leukocyte count &gt; 3,000/uL&#xD;
&#xD;
          -  Absolute neutrophil count &gt; 1,500/uL&#xD;
&#xD;
          -  Platelet count &gt; 100,000/uL&#xD;
&#xD;
          -  Total bilirubin normal&#xD;
&#xD;
          -  AST and ALT &lt; 2.5 times upper limit of normal&#xD;
&#xD;
          -  Creatinine normal OR creatinine clearance &gt; 60 mL/min&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior biologic therapy&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  At least 30 days since prior investigational agents&#xD;
&#xD;
          -  No concurrent dehydroepiandrosterone or androstenedione supplements&#xD;
&#xD;
          -  No concurrent chemotherapy or radiotherapy&#xD;
&#xD;
          -  No concurrent hormone therapy or immunotherapy (including trastuzumab [HerceptinÂ®])&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rodney F. Pommier, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Knight Cancer Institute at Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239-3098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>August 14, 2007</study_first_submitted>
  <study_first_submitted_qc>August 14, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2007</study_first_posted>
  <last_update_submitted>July 23, 2012</last_update_submitted>
  <last_update_submitted_qc>July 23, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IV breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <keyword>male breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

